Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide sur
05/29/2026
The World Gastroenterology Organisation established World Digestive Health Day to raise awareness about digestive health issues and promote preventative measures. Digestive problems affect millions around the globe, so it’s important to prioritize . As a global medical device company, we’re dedicated to providing solutions to take charge of gut health.
https://hubs.la/Q04gcT8t0
05/26/2026
is officially expanding into the United Arab Emirates and Turkey!
We’ve obtained key regulatory clearances for in these two major markets, already securing our first commercial sale in the UAE for the CellTolerance program. With and food intolerances impacting up to 27% of the population in these markets, our precision diagnostics are ready to make a major impact.
Read the full press release: https://hubs.ly/Q04hytGJ0
Cellvizio by Mauna Kea Technologies has obtained regulatory clearances for in the United Arab Emirates and Turkey. These approvals open doors to two of the world's most compelling markets for precision diagnostics where and food intolerances affect up to 27% of the population on average, and up to 39% of young adults in the UAE.
Building immediately on these clearances, we confirm our first commercial sale of Cellvizio in the UAE, dedicated specifically to the program. The region's thriving premium private healthcare sector and strong patient purchasing power make it uniquely suited to our commercial strategy.
Read the full press release: https://hubs.ly/Q04hwR6d0
Cellvizio by Mauna Kea Technologies has obtained regulatory clearances for in the United Arab Emirates and Turkey. These approvals open doors to two of the world's most compelling markets for precision diagnostics where and food intolerances affect up to 27% of the population on average, and up to 39% of young adults in the UAE.
Building immediately on these clearances, we confirm our first commercial sale of Cellvizio in the UAE, dedicated specifically to the program. The region's thriving premium private healthcare sector and strong patient purchasing power make it uniquely suited to our commercial strategy.
Read the full press release: https://hubs.la/Q04hnlVn0
Crohn’s Disease and Ulcerative Colitis are two chronic inflammatory bowel diseases ( ) that affect millions of people around the world. While not showing any outward signs of their condition, many struggle to get the support and understanding that they need.
To learn how can be superior to conventional severity scoring, visit: https://hubs.la/Q04gcT9k0
Crohn's & Colitis Foundation
The stakes for early detection have never been higher. For clinicians, the challenge isn't just treating the lesion, it’s navigating the long road to Complete Remission of Intestinal Metaplasia (CRIM).
We can't control the rise of the disease alone, but with advanced imaging, we can control how we find and treat it.
How it works: https://hubs.la/Q04fTYHg0
offers unprecedented cellular-level visualization, empowering physicians to understand and treat patients with greater precision unlike any other platform available today. This groundbreaking technology is transforming the landscape of healthcare.
Discover Cellvizio's transformative impact: https://hubs.la/Q04fQQpq0
05/06/2026
According to published data, pancreatic cysts are simultaneously over-resected and under-detected, making the crux of being wrong enormous in either direction. The latest insights from are clear: outperforms conventional pancreatic cyst fluid analysis (CEA, amylase, cytology, glucose) in differentiating benign from malignant or pre-malignant cysts helping ensure the right patients get surgery, and the right patients avoid it.
Get the full details: https://hubs.la/Q04fJRkn0
Putting the Pieces Together to Solve the Puzzle of Pancreatic Cyst Diagnosis A size-based, multimodal diagnostic strategy could close dangerous gaps in pancreatic cyst evaluation by combining tools to better distinguish benign from high-risk lesions, says Dr. Somashekar Krishna.
05/05/2026
New data from highlights a pivotal moment for patients struggling with unexplained gut issues. and SIBO diagnosis is moving away from "one-size-fits-all" and toward precision medicine with CellTolerance leading the way.
CLE ( ) can go beyond the surface giving physicians real-time, cellular-level visualization of the intestinal mucosa that conventional testing often misses. For IBS patients who have spent years searching for answers, the test represents a paradigm shift from diagnosis by exclusion to precision diagnosis.
Read the full science breakdown from DDW 2026 here:
The Science of IBS and SIBO: Emerging Tools Refine Diagnosis and Personalize Care Advances in microbiome science and immune-mediated food intolerance are expanding treatment options for patients with IBS and SIBO who have food-associated symptoms, says Dr. Sean Spencer.
05/04/2026
We are proud to be part of the 4th Annual Pancreatic Cyst Consortium at Digestive Disease Week® (DDW®), organized by Som Krishna, MD, MPH, which had record attendance! This major event brought together leading voices for insightful conversations on advancing pancreatic cyst diagnostic and management strategies, all focused on improving patient outcomes.
Thank you to all involved!
| Monday | 8:30am - 5pm |
| Tuesday | 8:30am - 5pm |
| Wednesday | 8:30am - 5pm |
| Thursday | 8:30am - 5pm |
| Friday | 8:30am - 5pm |